Discover how Indivior plans to overcome challenges in the competitive LAI market, drive SUBLOCADE's growth with FDA updates, and achieve long-term ...
Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...
Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the ...
Piper Sandler analyst David Amsellem maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...
Canaccord Genuity has adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) by reducing the stock's price target to $8.00 from the previous $9.00, while maintaining a Hold rating on the shares. The ...
Investing.com -- Piper Sandler upgraded Simon Property Group Inc (NYSE:SPG) to "Overweight" from "Neutral," citing stronger-than-expected earnings potential and a renewed focus on its real estate ...
Bernstein & Co. Salveen Richter; Analyst; Goldman Sachs Group, Inc. David Amsellem; Analyst; Piper Sandler & Co. Thank you, Julianne. Good afternoon, everyone, and welcome to our fourth quarter 2024 ...
James Bradner; Executive Vice President - Research and Development; Amgen Inc Peter Griffith; Executive Vice President and Chief Financial Officer; Amgen Inc Yaron Werber; Analyst; TD Cowen ...
Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...
Shares of Piper Sandler Companies stock opened at $319.81 on Monday. The business has a 50 day moving average price of $302.86 and a 200 day moving average price of $314.09. The company has a ...